Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anakinra - Swedish Orphan Biovitrum

Next Previous
X
Search
Drug Profile

Anakinra - Swedish Orphan Biovitrum

Alternative Names: 143090-92-0; Antril; Kinaret; Kineret; Recombinant human interleukin-1 receptor antagonist; rhIL-1ra; rIL-1ra; rIL1RN

Latest Information Update: 11 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; CHRU de Tours; Swedish Orphan Biovitrum
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antigouts; Antineoplastics; Antirheumatics; Recombinant proteins
  • Mechanism of Action Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes; Immunological disorders; Juvenile rheumatoid arthritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cryopyrin-associated periodic syndromes; Rheumatoid arthritis
  • Registered Adult-onset Still's disease; Autoimmune disorders; COVID-19 pneumonia; Familial Mediterranean fever; Juvenile rheumatoid arthritis
  • Phase III COVID 2019 infections
  • Phase II Gout; Non-Hodgkin's lymphoma
  • Discontinued Ankylosing spondylitis; Graft-versus-host disease; Osteoarthritis; Pneumococcal infections; Septic shock

Most Recent Events

  • 31 Dec 2023 Registered for Cryopyrin-associated periodic syndromes in China (SC) prior to December 2023
  • 31 Dec 2023 Registered for Familial Mediterranean fever in China (SC) prior to December 2023
  • 31 Oct 2023 Kite completes a phase II clinical trial in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (SC) (NCT04150913)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top